AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV
Description: 4 doses, orally, at birth (=\< 7 days of age) and at 6, 10 and 14 weeks of age
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rouvax
Description: 1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rouvax
Description: 1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
Study NCT02088775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Undergo PET-CT scan
Study NCT02088775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: Undergo PET-CT scan
Study NCT02088775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Description: Undergo standard radioembolization
Study NCT00661258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic drug monitoring feedback data
Description: All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
Study NCT03501693 — intervention group
Intervention type: DEVICE
Intervention: DBT plus S-View
Description: DBT plus S-View images
Study NCT03384784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
Study NCT03501693 — intervention group
Intervention type: DEVICE
Intervention: FFDM Alone
Description: FFDM alone images
Study NCT03803020 — intervention group
Intervention type: OTHER
Intervention: fractional flow reserve and SPECT detection
Description: fractional flow reserve and SPECT detection
Study NCT02938936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-natal visit scheduling
Description: This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
Study NCT02383511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SMT C1100
Description: Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
Study NCT02383511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SMT C1100
Description: Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
Study NCT02383511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SMT C1100
Description: Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
Study NCT02207374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
Study NCT02207374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitor
Description: Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
Study NCT01428804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
Study NCT01428804 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
Study NCT01272882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography monitoring
Description: Chest belt with 16 electrodes connected to the EIT device
Study NCT02494206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBX258
Description: Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
Study NCT03414697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
Study NCT03414697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
Study NCT00802828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine Tablets, 40 mg
Study NCT01860014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
Study NCT01860014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beractant
Description: Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
Study NCT03696875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multilevel Guided Discharge Planning
Description: Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
Study NCT03696875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT00702182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine)
Description: Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
Study NCT00702182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine)
Description: Metronomic Schedule Oral Vinorelbine 3 times a week
Study NCT00702182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily Oral Erlotinib 100 mg
Study NCT04378660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence for polyp detection
Description: Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
Study NCT03511872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic life support training
Description: A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group.
Study NCT04324255 — intervention group
Intervention type: PROCEDURE
Intervention: LT
Description: Liver transplantation
Study NCT03384784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
Study NCT01504451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILR insertion
Description: Insertion of implantable loop recorder
Study NCT01504451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: AF ablation
Study NCT03270813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training plus RAGE-Control
Description: RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
Study NCT03270813 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxation training plus Sham Videogame
Description: The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
Study NCT03120208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
Description: The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
Study NCT03384784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
Study NCT03384784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
Study NCT03120208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The GAD-7 with a discrimination threshold ≥10.
Description: The GAD-7 with a discrimination threshold ≥10.
Study NCT03120208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
Description: Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
Study NCT01867294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Given PO
Study NCT01867294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Management of Therapy Complications
Description: Moisturizer given topically
Study NCT01867294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given topically
Study NCT01867294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01867294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01867294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01867294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Given topically
Study NCT01867294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Given topically
Study NCT01867294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hydrocortisone
Description: Given topically
Study NCT03192995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorcaserin
Description: lorcaserin 20 mg tablet
Study NCT03192995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo 20 mg. tablet
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Substance use counseling
Description: Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance use counseling
Description: Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ACASI
Description: Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACASI
Description: Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
Study NCT03192995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine metabolites
Description: Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
Study NCT03192995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine metabolites
Description: Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ecological Momentary Assessment (EMA)
Description: EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological Momentary Assessment (EMA)
Description: EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Balloon Analogue Risk Task (BART)
Description: BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Analogue Risk Task (BART)
Description: BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Qualitative Exit Interview
Description: The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
Study NCT03192995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Exit Interview
Description: The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
Study NCT03108170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perineal massage program
Description: The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
Study NCT03108170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercise program
Description: The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
Study NCT03108170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational pelvic floor dysfunction prevention program
Description: This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
Study NCT01621451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and/or clopidogrel
Description: Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
Study NCT01621451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and/or clopidogrel
Description: Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
Study NCT04987099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 550 mg/day Choline
Description: Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
Study NCT04987099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 25 mg/day Choline
Description: Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
Study NCT03133273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncogramme®
Description: Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
Study NCT03929159 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood biospecimen collection
Study NCT03751800 — intervention group
Intervention type: DRUG
Intervention: Chronic hormonal treatment
Description: Drugs used in this study are described by the physicians during routine gynecological visits
Study NCT04441684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample for serological test
Description: Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.
Study NCT00754520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic On Metal
Description: Ceramic on Metal articulation using M2a-38™ mm cup
Study NCT00754520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal on Metal
Description: Metal on Metal articulation using M2a-38™ mm cup
Study NCT04598451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
Study NCT04598451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection of placebo
Study NCT04598451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral prednisone tablets
Study NCT01952106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: play computer game
Study NCT06336941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasonographic scan with a 70 MHz probe